OSCR

Oleic acid improves pathological changes in Aβ1-42-induced astrocytes and Alzheimer's disease mouse models through PKA/ACACB/CPT1A.

Overview

Authors: YiBo Xie1,2, Jianan Tian1, Hui Li1, Yahui Peng3, Mingjie Li1, Yun Wu1
  1. Department of Neurology, Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
  2. Department of Biochemistry and Molecular Biology, School of Basic Medicine, Harbin Medical University, Harbin, Heilongjiang, China
  3. Harbin Medical University, Harbin, Heilongjiang, China
Journal: Frontiers in neuroscience, volume 20, article 1771310
Dates: received 19 December 2025; accepted 26 March 2026; published online 15 April 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.3389/fnins.2026.1771310 · PMID 42063966 · PMCID PMC13125043 · OpenAlex W7154449398
Open access: gold, a free copy (OpenAlex)
Categories: mouse (organism), Alzheimer's / dementia (population), cellular / molecular (subfield)
Methods: Statistics, Machine learning
Keywords: ACACB, Alzheimer’s disease, astrocyte, fatty acid, oleic acid
Topic: Fatty Acid Research and Health (Nutrition and Dietetics, Nursing), according to OpenAlex
Funding: Postgraduate Research & Practice Innovation Program of Harbin Medical University (YJSCX2024-45HYD); First-Class Disciplines and Specialties Project of the Second Affiliated Hospital of Harbin Medical University (YLXK202007)
Citations: cited by 1 paper (Europe PMC); 71 references in the paper

Abstract

Background: Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder. Emerging evidence indicates that fatty acid oxidation is impaired in both patients with AD and AD animal models. In the brain, fatty acid metabolism occurs predominantly in astrocytes. Diets enriched in monounsaturated fatty acids (MUFAs) are often recommended for individuals with AD. Oleic acid (OA), a common dietary MUFA, has been shown to reduce amyloid plaque accumulation in transgenic mouse models of AD. Moreover, OA decreases the expression of acetyl-CoA carboxylase beta (ACACB/ACC2), a key regulator of fatty acid β-oxidation. However, the precise mechanism by which OA may alleviate amyloid plaque deposition through modulation of brain fatty acid metabolism remains unclear.

Objective: To determine whether dietary OA supplementation partially restores astrocytic fatty acid metabolism by suppressing ACACB and enhancing fatty acid β-oxidation, thereby attenuating AD-related pathology.

Methods: Using NHANES 2011–2014 data, we applied survey-weighted multivariable logistic regression to examine the association between energy-adjusted MUFA intake and low cognitive function, with adjustment for multiple testing. We then screened GEO datasets to identify AD-associated genes involved in fatty acid metabolic dysregulation, identifying ACACB as a candidate target. The expression of ACACB and its downstream effector carnitine palmitoyltransferase 1A (CPT1A) were validated in mouse and cell models. APP/PS1 mice received dietary OA supplementation, followed by behavioral testing and brain histopathological analyses. In parallel, an Aβ1–42-induced astrocyte injury model was used to assess lipid droplet accumulation, mitochondrial function, and cellular energy metabolism. ACACB knockdown/overexpression and CPT1A overexpression were used to test pathway-specific effects of OA.

Results: Higher MUFA intake was associated with better cognitive function. ACACB as a key fatty acid metabolism-related gene in AD. In APP/PS1 mice, OA improved cognitive performance and reduced Aβ plaque deposition, accompanied by decreased ACACB and increased CPT1A expression in brain tissue. In vitro, OA modulated ACC2 activity through protein kinase A (PKA) signaling, increased fatty acid β-oxidation, reduced lipid droplet accumulation, restored mitochondrial membrane potential and ATP production, and enhanced astrocyte-mediated support of neuronal synaptic growth.

Conclusion: OA ameliorates AD-related pathology and cognitive impairment by restoring astrocytic fatty acid β-oxidation through the PKA/ACACB/CPT1A pathway.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Other data links

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author/s.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 29 September 2026: the first record

Recorded: type, language, journal, volume, pages, dates, 6 authors, 5 keywords, 2 funders, 70 references.

Cite

This paper

Xie, Y., Tian, J., Li, H., Peng, Y., Li, M., & Wu, Y. (2026). Oleic acid improves pathological changes in Aβ1-42-induced astrocytes and Alzheimer's disease mouse models through PKA/ACACB/CPT1A. Frontiers in neuroscience, 20, 1771310. https://doi.org/10.3389/fnins.2026.1771310

BibTeX

@article{xie2026oleic,
author = {Xie, YiBo and Tian, Jianan and Li, Hui and Peng, Yahui and Li, Mingjie and Wu, Yun},
title = {{Oleic acid improves pathological changes in Aβ1-42-induced astrocytes and Alzheimer's disease mouse models through PKA/ACACB/CPT1A}},
journal = {Frontiers in neuroscience},
year = {2026},
month = apr,
volume = {20},
pages = {1771310},
publisher = {Frontiers Media SA},
issn = {1662-4548},
doi = {10.3389/fnins.2026.1771310},
url = {https://doi.org/10.3389/fnins.2026.1771310},
pmid = {42063966},
pmcid = {PMC13125043}
}

RIS

TY - JOUR
AU - Xie, YiBo
AU - Tian, Jianan
AU - Li, Hui
AU - Peng, Yahui
AU - Li, Mingjie
AU - Wu, Yun
TI - Oleic acid improves pathological changes in Aβ1-42-induced astrocytes and Alzheimer's disease mouse models through PKA/ACACB/CPT1A
T2 - Frontiers in neuroscience
J2 - Front Neurosci
PY - 2026
DA - 2026/04/15
VL - 20
SP - 1771310
SN - 1662-4548
PB - Frontiers Media SA
DO - 10.3389/fnins.2026.1771310
UR - https://doi.org/10.3389/fnins.2026.1771310
LA - en
ER -

CSL-JSON

{
"id": "10.3389/fnins.2026.1771310",
"type": "article-journal",
"title": "Oleic acid improves pathological changes in Aβ1-42-induced astrocytes and Alzheimer's disease mouse models through PKA/ACACB/CPT1A",
"container-title": "Frontiers in neuroscience",
"author": [
{
"family": "Xie",
"given": "YiBo"
},
{
"family": "Tian",
"given": "Jianan"
},
{
"family": "Li",
"given": "Hui"
},
{
"family": "Peng",
"given": "Yahui"
},
{
"family": "Li",
"given": "Mingjie"
},
{
"family": "Wu",
"given": "Yun"
}
],
"container-title-short": "Front Neurosci",
"volume": "20",
"page": "1771310",
"DOI": "10.3389/fnins.2026.1771310",
"PMID": "42063966",
"PMCID": "PMC13125043",
"ISSN": "1662-4548",
"publisher": "Frontiers Media SA",
"URL": "https://doi.org/10.3389/fnins.2026.1771310",
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
15
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1038/s41598-024-80401-6
Interpretable machine learning-driven biomarker identification and validation for Alzheimer's disease.
Journal: Scientific reports
In common: NCBI GEO GSE109887, Alzheimer's / dementia, 3 references
[2] doi:10.1111/jnc.16032
Brain energy metabolism: A roadmap for future research.
Journal: Journal of neurochemistry
In common: cellular / molecular, 6 references
[3] doi:10.1186/s13024-022-00566-4
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.
Journal: Molecular neurodegeneration
In common: Alzheimer's / dementia, cellular / molecular, 6 references
[4] doi:10.1038/s42003-024-06751-z
Cell-specific expression of key mitochondrial enzymes limits OXPHOS in astrocytes of the adult human neocortex and hippocampal formation.
Journal: Communications biology
In common: cellular / molecular, 5 references
[5] doi:10.3389/fnins.2022.989174
Drug repurposing using meta-analysis of gene expression in Alzheimer's disease.
Journal: Frontiers in neuroscience
In common: NCBI GEO GSE109887, Alzheimer's / dementia, cellular / molecular, 1 reference
[6] doi:10.1038/s41467-022-29506-y [code]
Stearoyl-CoA Desaturase inhibition reverses immune, synaptic and cognitive impairments in an Alzheimer's disease mouse model.
Journal: Nature communications
In common: Alzheimer's / dementia, mouse, cellular / molecular, 4 references
[7] doi:10.3389/fnagi.2022.919614
Identification of diagnostic signatures associated with immune infiltration in Alzheimer's disease by integrating bioinformatic analysis and machine-learning strategies.
Journal: Frontiers in aging neuroscience
In common: NCBI GEO GSE109887, Alzheimer's / dementia, 1 reference
[8] doi:10.1186/s13024-023-00625-4
ACSS2-dependent histone acetylation improves cognition in mouse model of Alzheimer's disease.
Journal: Molecular neurodegeneration
In common: Alzheimer's / dementia, mouse, 4 references
[9] doi:10.1371/journal.pbio.3003192
Seizure evolution in a mouse model of West syndrome involves complex and time-dependent synapse remodeling, gliosis and alterations in lipid metabolism.
Journal: PLoS biology
In common: mouse, cellular / molecular, 4 references
[10] doi:10.1186/s13024-025-00840-1 [code]
Alzheimer's disease protective allele of Clusterin modulates neuronal excitability through lipid-droplet-mediated neuron-glia communication.
Journal: Molecular neurodegeneration
In common: Alzheimer's / dementia, mouse, cellular / molecular, 4 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.